Disulfiram induces copper-dependent stimulation of reactive oxygen species and activation of the extrinsic apoptotic pathway in melanoma

Melanoma Research

Volumn 20, Issue 1, 2010, Pages 11-20

  Morrison, Brian W ^a   Doudican, Nicole A ^a   Patel, Kirtesh R ^a   Orlow, Seth J ^a,b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NEW YORK UNIVERSITY   (United States)

Author keywords

Apoptosis; Copper; Disulfiram; Melanoma; Reactive oxygen species

Indexed keywords

BENZYLOXYCARBONYLISOLEUCYLGLUTAMYLTHREONYLASPARTYL FLUOROMETHYL KETONE; COPPER SULFATE; DISULFIRAM; REACTIVE OXYGEN METABOLITE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENTIATION; HUMAN; HUMAN CELL; MELANOMA; PRIORITY JOURNAL;

APOPTOSIS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; COPPER; COPPER SULFATE; DISULFIRAM; HUMANS; MELANOMA; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; SKIN NEOPLASMS;

EID: 75749092675     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/CMR.0b013e328334131d     Document Type: Article

References (63)

1. Houghton A, Legha S, Bajorin DF. Chemotherapy for metastatic melanoma. In: Balch HA, Milton C, Sober S. editors. Cutaneous melanoma. Philadelphia: J. B. Lippincott; 1992. pp. 498-508.
2. Meyskens FL Jr, Chau HV, Tohidian N, Buckmeier J. Luminol-enhanced chemiluminescent response of human melanocytes and melanoma cells to hydrogen peroxide stress. Pigment Cell Res 1997; 10:184-189.
3. Gidanian S, Mentelle M, Meyskens FL Jr, Farmer PJ. Melanosomal damage in normal human melanocytes induced by UVB and metal uptake - a basis for the pro-oxidant state of melanoma. Photochem Photobiol 2008; 84:556-564.
4. Wittgen HG, Van Kempen LC. Reactive oxygen species in melanoma and its therapeutic implications. Melanoma Res 2007; 17:400-409.
5. Balch CM, Soong SJ, Shaw HM, Urist MM, McCarthy WH. An analysis of prognostic factors in 8500 patients with cutaneous melanoma. In: Balch CM, Houghton AN, Milton GW, Sober AJ, Soong SJ, editors. Cutaneous melanoma. Philadelphia: JB Lippincott; 1991. p. 165.
6. Warycha MA, Christos PJ, Mazumdar M, Darvishian F, Shapiro RL, Berman RS, et al. Changes in the presentation of nodular and superficial spreading melanomas over 35 years. Cancer 2008; 113:3341-3348.
7. Cen D, Brayton D, Shahandeh B, Meyskens FL Jr, Farmer PJ. Disulfiram facilitates intracellular Cu uptake and induces apoptosis in human melanoma cells. J Med Chem 2004; 47:6914-6920.
8. Cen D, Gonzalez RI, Buckmeier JA, Kahlon RS, Tohidian NB, Meyskens FL Jr. Disulfiram induces apoptosis in human melanoma cells: a redox-related process. Mol Cancer Ther 2002; 1:197-204.
9. Grant SW, Kyshtoobayeva AS, Kurosaki T, Jakowatz J, Fruehauf JP. Mutant p53 correlates with reduced expression of thrombospondin-1, increased angiogenesis, and metastatic progression in melanoma. Cancer Detect Prev 1998; 22:185-194.
10. Aoyama Y, Avruch J, Zhang XF. Nore1 inhibits tumor cell growth independent of Ras or the MST1/2 kinases. Oncogene 2004; 23:3426-3433.
11. Fernandez Y, Verhaegen M, Miller TP, Rush JL, Steiner P, Opipari AWJr, et al. Differential regulation of noxa in normal melanocytes and melanoma cells by proteasome inhibition: therapeutic implications. Cancer Res 2005; 65: 6294-6304.
12. Grossman D, NcNiff JM, Li F, Altieri DC. Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma. J Invest Dermatol 1999; 113:1076-1081.
13. Smalley KS, Lioni M, Dalla Palma M, Xiao M, Desai B, Egyhazi S, et al. Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas. Mol Cancer Ther 2008; 7:2876-2883.
14. Somasundaram R, Swoboda R, Caputo L, Otvos L, Weber B, Volpe P, et al. Human leukocyte antigen-A2-restricted CTL responses to mutated BRAF peptides in melanoma patients. Cancer Res 2006; 66:3287-3293.
15. Sousa JF, Espreafico EM. Suppression subtractive hybridization profiles of radial growth phase and metastatic melanoma cell lines reveal novel potential targets. BMC Cancer 2008; 8:19.
16. Bennett DC, Cooper PJ, Hart IR. A line of non-tumorigenic mouse melanocytes, syngeneic with the B16 melanoma and requiring a tumour promoter for growth. Int J Cancer 1987; 39:414-418.
17. Manga P, Orlow SJ. Inverse correlation between pink-eyed dilution protein expression and induction of melanogenesis by bafilomycin A1. Pigment Cell Res 2001; 14:362-367.
18. Doudican N, Rodriguez A, Osman I, Orlow SJ. Mebendazole induces apoptosis via Bcl-2 inactivation in chemoresistant melanoma cells. Mol Cancer Res 2008; 6:1308-1315.
19. Faiman MD, Jensen JC, Lacoursiere RB. Elimination kinetics of disulfiram in alcoholics after single and repeated doses. Clin Pharmacol Ther 1984; 36:520-526.
20. Orrenius S, Nobel CS, van den Dobbelsteen DJ, Burkitt MJ, Slater AF. Dithiocarbamates and the redox regulation of cell death. Biochem Soc Trans 1996; 24:1032-1038.
21. Somers PK, Medford RM, Saxena U. Dithiocarbamates: effects on lipid hydroperoxides and vascular inflammatory gene expression. Free Radic Biol Med 2000; 28:1532-1537.
22. Brar SS, Grigg C, Wilson KS, Holder WD Jr, Dreau D, Austin C, Foster M. Disulfiram inhibits activating transcription factor/cyclic AMP-responsive element binding protein and human melanoma growth in a metal-dependent manner in vitro, in mice and in a patient with metastatic disease. Mol Cancer Ther 2004; 3:1049-1060.
23. Chen D, Cui QC, Yang H, Dou QP. Disulfiram, a clinically used antialcoholism drug and copper-binding agent, induces apoptotic cell death in breast cancer cultures and xenografts via inhibition of the proteasome activity. Cancer Res 2006; 66:10425-10433.
24. Viola-Rhenals M, Rieber MS, Rieber M. Role of peroxidases, thiols and Bak/ Bax in tumor cell susceptibility to Cu(DEDTC)2. Biochem Pharmacol 2007; 74:841-850.
25. Kaufmann SH, Desnoyers S, Ottaviano Y, Davidson NE, Poirier GG. Specific proteolytic cleavage of poly(ADP-ribose) polymerase: an early marker of chemotherapy-induced apoptosis. Cancer Res 1993; 53:3976-3985.
26. Wallach-Dayan SB, Izbicki G, Cohen PY, Gerstl-Golan R, Fine A, Breuer R. Bleomycin initiates apoptosis of lung epithelial cells by ROS but not by Fas/ FasL pathway. Am J Physiol Lung Cell Mol Physiol 2006; 290:L790-L796.
27. Baumert J, Schmidt M, Giehl KA, Volkenandt M, Plewig G, Wendtner C, Schmid-Wendtner MH. Time trends in tumour thickness vary in subgroups: analysis of 6475 patients by age, tumour site and melanoma subtype. Melanoma Res 2009; 19:24-30.
28. Barnhill RL, Fine JA, Roush GC, Berwick M. Predicting five-year outcome for patients with cutaneous melanoma in a population-based study. Erratum appears in Cancer 1997 January 15;79(2):423. Cancer 1996; 78: 427-432.
29. Weyers W, Euler M, Diaz-Cascajo C, Schill WB, Bonczkowitz M. Classification of cutaneous malignant melanoma: a reassessment of histopathologic criteria for the distinction of different types. Cancer 1999; 86:288-299.
30. Jaeger J, Koczan D, Thiesen HJ, Ibrahim SM, Gross G, Spang R, Kunz M. Gene expression signatures for tumor progression, tumor subtype, and tumor thickness in laser-microdissected melanoma tissues. Clin Cancer Res 2007; 13:806-815.
31. Liu W, Kelly JW, Trivett M, Murray WK, Dowling JP, Wolfe R, et al. Distinct clinical and pathological features are associated with the BRAF[T1799A(V600E)] mutation in primary melanoma. J Invest Dermatol 2007; 127:900-905.
32. Ng B, Zakrzewski J, Warycha M, Christos PJ, Bajorin DF, Shapiro RL, et al. Shedding of distinct cryptic collagen epitope (HU177) in sera of melanoma patients. Clin Cancer Res 2008; 14:6253-6258.
33. Atkins M. The role of cytotoxic chemotherapeutic agents either alone or in combination with biological response modifiers. In: Kirkwood JK, editor. Molecular diagnosis, prevention & therapy of melanoma. New York: Marcel Dekker; 1997. p. 219.
34. Houghton AN, Legha S, Bajorin DF. Chemotherapy for metastatic melanoma. In: Balch CM, Houghton AN, Milton GW, Sober AJ, Soong SJ, editors. Cutaneous melanoma. Philadelphea: JB Lippincott; 1999. p. 498.
35. Chung KC, Park JH, Kim CH, Lee HW, Sato N, Uchiyama Y, Ahn YS. Novel biphasic effect of pyrrolidine dithiocarbamate on neuronal cell viability is mediated by the differential regulation of intracellular zinc and copper ion levels, NF-kappaB, and MAP kinases. J Neurosci Res 2000; 59:117-125.
36. Erl W, Weber C, Hansson GK. Pyrrolidine dithiocarbamate-induced apoptosis depends on cell type, density, and the presence of Cu(2 + ) and Zn(2 + ). Am J Physiol Cell Physiol 2000; 278:C1116-C1125.
37. Nobel CI, Kimland M, Lind B, Orrenius S, Slater AF. Dithiocarbamates induce apoptosis in thymocytes by raising the intracellular level of redox-active copper. J Biol Chem 1995; 270:26202-26208.
38. Abiaka C, Olusi S, Al-Awadhi A. Reference ranges of copper and zinc and the prevalence of their deficiencies in an Arab population aged 15-80 years. Biol Trace Elem Res 2003; 91:33-43.
39. Diez M, Arroyo M, Cerdan FJ, Munoz M, Martin MA, Balibrea JL. Serum and tissue trace metal levels in lung cancer. Oncology 1989; 46:230-234.
40. Fisher GL, Spitler LE, McNeill KL, Rosenblatt LS. Serum copper and zinc levels in melanoma patients. Cancer 1981; 47:1838-1844.
41. Zowczak M, Iskra M, Torlinski L, Cofta S. Analysis of serum copper and zinc concentrations in cancer patients. Biol Trace Elem Res 2001; 82:1-8.
42. Borovansky J, Riley PA. The effect of divalent cations on Cloudman melanoma cells. Eur J Cancer Clin Oncol 1983; 19:91-99.
43. Boldin MP, Goncharov TM, Goltsev YV, Wallach D. Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1- and TNF receptor-induced cell death. Cell 1996; 85:803-815.
44. Kischkel FC, Hellbardt S, Behrmann I, Germer M, Pawlita M, Krammer PH, Peter ME. Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO J 1995; 14:5579-5588.
45. Muzio M, Chinnaiyan AM, Kischkel FC, O'Rourke K, Shevchenko A, Ni J, et al. FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex. Cell 1996; 85:817-827.
46. Fulda S, Sieverts H, Friesen C, Herr I, Debatin KM. The CD95 (APO-1/Fas) system mediates drug-induced apoptosis in neuroblastoma cells. Cancer Res 1997; 57:3823-3829. (Pubitemid 27381230)
47. Muller M, Strand S, Hug H, Heinemann EM, Walczak H, Hofmann WJ, et al. Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. J Clin Invest 1997; 99:403-413.
48. Bantel H, Engels IH, Voelter W, Schulze-Osthoff K, Wesselborg S. Mistletoe lectin activates caspase-8/FLICE independently of death receptor signaling and enhances anticancer drug-induced apoptosis. Cancer Res 1999; 59:2083-2090.
49. Nica AF, Tsao CC, Watt JC, Jiffar T, Kurinna S, Jurasz P, et al. Ceramide promotes apoptosis in chronic myelogenous leukemia-derived K562 cells by a mechanism involving caspase-8 and JNK. Cell Cycle 2008; 7:3362-3370.
50. Su CL, Lin TY, Lin CN, Won SJ. Involvement of caspases and apoptosisinducing factor in bufotalin-induced apoptosis of Hep 3B cells. J Agri Food Chem 2009; 57:55-61.
51. Wesselborg S, Engels IH, Rossmann E, Los M, Schulze-Osthoff K. Anticancer drugs induce caspase-8/FLICE activation and apoptosis in the absence of CD95 receptor/ligand interaction. Blood 1999; 93:3053-3063.
52. Wang L, Azad N, Kongkaneramit L, Chen F, Lu Y, Jiang BH, Rojanasakul Y. The Fas death signaling pathway connecting reactive oxygen species generation and FLICE inhibitory protein down-regulation. J Immunol 2008; 180:3072-3080.
53. Kwon D, Choi K, Choi C, Benveniste EN. Hydrogen peroxide enhances TRAIL-induced cell death through up-regulation of DR5 in human astrocytic cells. Biochem Biophys Res Commun 2008; 372:870-874.
54. Lee MW, Park SC, Yang YG, Yim SO, Chae HS, Bach JH, et al. The involvement of reactive oxygen species (ROS) and p38 mitogen-activated protein (MAP) kinase in TRAIL/Apo2L-induced apoptosis. FEBS Lett 2002; 512:313-318.
55. Kazakov SA, Astashkina TG, Mamaev SV, Vlassov VV. Site-specific cleavage of single-stranded DNAs at unique sites by a copper-dependent redox reaction. Nature 1988; 335:186-188.
56. Lunec J, Wickens DG, Graff TL, Dormand TL. Inflammatory diseases and copper: the metabolic and therapeutic roles of copper and other essential metalloelements in humans. In: Sorenson JRJ, editor. Inflammatory disease and copper: the metabolic and therapeutic roles of copper and other essential metalloelements in humans. Totowa, NJ: Humana; 1982. pp. 231-242.
57. Zhai Q, Ji H, Zheng Z, Yu X, Sun L, Liu X. Copper induces apoptosis in BA/F3beta cells: bax, reactive oxygen species, and NFkappaB are involved. J Cellular Physiol 2000; 184:161-170.
58. Garbutt JC, West SL, Carey TS, Lohr KN, Crews FT. Pharmacological treatment of alcohol dependence: a review of the evidence. (see comment). JAMA 1999; 281:1318-1325.
59. Valeriote F, Grates HE. Potentiation of nitrogen mustard cytotoxicity by disulfiram, diethyldithiocarbamic acid, and diethylamine in mice. Cancer Res 1989; 49:6658-6661.
60. Wang W, McLeod HL, Cassidy J. Disulfiram-mediated inhibition of NF-kappaB activity enhances cytotoxicity of 5-fluorouracil in human colorectal cancer cell lines. Int J Cancer 2003; 104:504-511.
61. Ellenhorn M. Disulfiram, in ellenhorn's medical toxicology. Balitmore, Maryland: Lippincott, Willams & Wilkins; 1997. pp. 1356-1362.
62. O'Day S, Gonzalez R, Lawson D, Weber R, Hutchins L, Anderson C, et al. Subgroup analysis of efficacy and safety analysis of a randomized, double-blinded controlled phase II study of STA-4783 in combination with paclitaxel in patients with metastatic melanoma. In American Society for Clinical Oncology Annual Meeting: Chicago, IL. J Clin Oncol 2007; 25 (Suppl; abstr 8528):18s.
63. Hauschild A, Eggermount AM, Jacobson E, O'Day SJ. Phase III, randomized, double-blind study of elesclomol and paclitaxel Versus paclitaxel alone in stage IV metastatic melanoma (MM). In American Society of Clinical Oncology Annual Meeting. 2009: Orlando, FL. p. J Clin Oncol 2009; 27 (Suppl; abstr LBA9012):18s.